Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE-1 Trial?
Novo Nordisk(US:NVO) Seeking Alphaยท2024-11-25 04:28Group 1 - Novo Nordisk is currently out of favor among investors in the second half of the year, along with its peers in the obesity market [2] - The lack of upside revisions to the full-year revenue has characterized this period for Novo Nordisk [2]